Are remissions for AML patients 'better' after daunorubicin and cytarabine lipos...
Prof Daniel Ryan - University of Rochester, Rochester, USA
Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B-...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019